CTNM Q4 2025 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$85,000

Operating Income

-$17M

Net Income

-$15M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$277M

Total Liabilities

$16M

Stockholders' Equity

$261M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$85,000	$0	—
Operating Income	-$17M	$85M	-120.2%
Net Income	-$15M	-$15M	-4.1%